

Objective

Delafloxacin is a broad-spectrum fluoroquinolone antibacterial approved by EMA and FDA for treatment of acute bacterial skin and skin structure infections, and community-acquired pneumonia (CAP).


The objective of this study was the analysis of the susceptibilities to delafloxacin for recent European clinical isolates of *Streptococcus pneumoniae*, *Haemophilus influenzae* and methicillin-susceptible *Staphylococcus aureus* (MSSA) from CAP and lower respiratory tract infections (LRTI).

Methods

- CAP and LRTI isolates were consecutively collected at 34 medical centres from 18 European countries participating in the SENTRY Antimicrobial Surveillance Program during 2018-2021.
- Susceptibility testing was performed with CLSI broth microdilution, and EUCAST interpretive criteria were applied.
-

Results

Results



Results

Acknowledgements

Contact